KORU Medical Systems (NASDAQ:KRMD) Price Target Raised to $4.00

KORU Medical Systems (NASDAQ:KRMD) had its price target boosted by Canaccord Genuity Group from $3.00 to $4.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

KRMD has been the topic of a number of other research reports. B. Riley assumed coverage on KORU Medical Systems in a research note on Thursday, July 25th. They issued a “buy” rating and a $4.00 price objective on the stock. Piper Sandler boosted their price target on shares of KORU Medical Systems from $3.00 to $3.50 and gave the stock an “overweight” rating in a research report on Thursday.

KORU Medical Systems Trading Up 2.9 %

NASDAQ KRMD opened at $3.17 on Thursday. The company has a current ratio of 2.99, a quick ratio of 3.27 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a 12 month low of $1.98 and a 12 month high of $3.40. The company’s 50 day simple moving average is $2.67 and its 200 day simple moving average is $2.48.

Institutional Investors Weigh In On KORU Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of KRMD. Aaron Wealth Advisors LLC acquired a new position in shares of KORU Medical Systems in the 2nd quarter worth $28,000. Allspring Global Investments Holdings LLC acquired a new stake in KORU Medical Systems during the 2nd quarter worth about $28,000. XTX Topco Ltd purchased a new stake in KORU Medical Systems during the third quarter valued at about $34,000. Legato Capital Management LLC acquired a new position in shares of KORU Medical Systems in the second quarter worth about $35,000. Finally, Virtu Financial LLC purchased a new position in shares of KORU Medical Systems in the first quarter worth approximately $63,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.